Aegis Equities Research Announce Health and Life Science Review, August 2006

The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones. Some financial data is also presented. In our feature article in this issue we look at how the nature of the shareholders on a company's register, and the way a company handles communications with its shareholders, can provide investors useful information about biotechnology stocks.

The following company profiles have been covered by the report;

Agenix Limited (ASX: AGX)
Analytica (ASX: ALT)
EQiTX (ASX: EQX)
Genetic Technologies (ASX: GTG)
Metabolic Pharmaceuticals (ASX: MBP)
Narhex Life Sciences (ASX: NLS)
Phylogica (ASX: PYC)
Psiron (ASX: PSX)
pSivida (ASX: PSD)
Rockeby biomed Limited (ASX: RBY)
Solagran (ASX: SLA)
Virax (ASX: VHL)

To download the report, please visit;
www.aer.com.au

NB: This report has been commissioned and as such Aegis has received a fee for its publication. However, under no circumstances has Aegis been influenced, either directly or indirectly, in making statements and/or recommendations contained in this report.



Related Companies

Solagran Limited
      

Resapp Health Ltd

PYC Therapeutics Ltd
         

Psivida Limited
  

Psiron Ltd

Prescient Therapeutics Ltd
            

Pathway Biomed Limited

Metabolic Pharmaceuticals Limited

Genetic Technologies Limited
      

Analytica Limited

Agenix Limited
     

Aegis Equities Research